Top Stocks on the Rise: Vistra, Argenx, and Flutter Lead the Charge

Generated by AI AgentAinvest Market Brief
Wednesday, Sep 25, 2024 6:30 pm ET1min read
JEF--
MS--
SPYU--
VST--
1. Vistrarp. (NYSE: VST)
Vistrarp. gained solidly by 5.91%. Jefferies, Morgan Stanley, and BMO Capital maintain positive ratings on Vistra, adjusting price targets to $137, $132, and $125 respectively. Vistra's mid-year report shows revenue of $68.99 billion, down 9.39% year-over-year.

2. Argenx Se (Nasdaq: ARGX)
Argenx Se gained solidly by 5.63%. JP Morgan, Barclays, Baird, and Guggenheim maintain positive ratings on argenx, with target prices ranging from $515 to $640. The company reported a 76.53% increase in revenue to $9.02 billion for H1 2024, with a net loss of $325.3 million.

3. Flutter Entertainment Plc (NYSE: FLUT)
Flutter Entertainment Plc gained solidly by 5.11%. Flutter received multiple analyst ratings: Needham initiated with a "Buy" and a $270 target, Barclays with "Overweight" at $263, and Morgan Stanley with "Overweight" at $247. The company reported 2024 H1 revenue of $70.08 billion, up 18.4% year-on-year.

4. Constellation Energy (Nasdaq: CEG)
Constellation Energy gained solidly by 3.7%. Constellation Energy has secured a 20-year power purchase agreement with Microsoft. Barclays and Keybanc maintain overweight ratings with price targets at $280 and $265, respectively. RBC Capital rates it sector perform at $214, while Jefferies initiates coverage with a hold rating at $183.

5. Vertiv Holdings (NYSE: VRT)
Vertiv Holdings gained solidly by 3.47%. Vertiv Holdings reported H1 2024 revenue of $35.92 billion, up 10.34% year-on-year, with net profit at $1.72 billion. Mizuho and Goldman Sachs have rated Vertiv Holdings as "Outperform" and "Buy", with target prices of $92.00 and $104.00, respectively.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet